| Bioactivity | Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor[1][2]. |
| Name | Lesabelimab |
| CAS | 2475402-56-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021. [2]. Masugi Y, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 Aug;66(8):1463-1473. |